公开(公告)号：US20230347012A1

公开(公告)日：2023-11-02

申请号：US18042573

申请日：2021-08-31

Applicant: Regents of the University of Minnesota

Inventor： Chen Guo ,  Jafar Golzarian

IPC: A61L24/10 ,  C08F20/56 ,  A61L24/00

CPC classification number: A61L24/108 ,  C08F20/56 ,  A61L24/0015 ,  A61L2430/36

Abstract: The present disclosure is generally directed to an embolic material in the form of a microparticle. The embolic material generally includes an alkene functionalized biopolymer. For instance, the embolic material may include a methacrylamide functionalized biopolymer. In some examples, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

公开(公告)号：US11439725B2

公开(公告)日：2022-09-13

申请号：US16206199

申请日：2018-11-30

Applicant: Regents of the University of Minnesota

Inventor： Jafar Golzarian ,  Lihui Weng

IPC: A61K49/18 ,  A61L24/08 ,  A61L24/00

Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

公开(公告)号：US20190091368A1

公开(公告)日：2019-03-28

申请号：US16206199

申请日：2018-11-30

Applicant: Regents of the University of Minnesota

Inventor： Jafar Golzarian ,  Lihui Weng

IPC: A61L24/08 ,  A61L24/00 ,  C08L5/08 ,  C08L1/28

Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

公开(公告)号：US10182979B2

公开(公告)日：2019-01-22

申请号：US15466301

申请日：2017-03-22

Applicant: Regents of the University of Minnesota ,  EmboMedics, Inc.

Inventor： Lihui Weng ,  Jafar Golzarian ,  Omid Souresrafil

IPC: A61K8/73 ,  A61K8/02 ,  A61K31/745 ,  A61Q11/00 ,  A61Q19/00 ,  A61Q19/08

Abstract: The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.

公开(公告)号：US20180078328A1

公开(公告)日：2018-03-22

申请号：US15705403

申请日：2017-09-15

Applicant: Regents of the University of Minnesota

Inventor： Michael Rosenberg ,  Sean Lester Moen ,  Jafar Golzarian

IPC: A61B90/00 ,  A61B34/20 ,  A61B17/04 ,  A61B17/34

CPC classification number: A61B90/39 ,  A61B17/0469 ,  A61B17/3403 ,  A61B34/20 ,  A61B2017/00809 ,  A61B2017/0441 ,  A61B2017/0464 ,  A61B2017/3413 ,  A61B2034/2051 ,  A61B2034/2063 ,  A61B2090/3762 ,  A61B2090/3908 ,  A61B2090/397 ,  A61B2090/3983 ,  A61B2090/3987 ,  A61B2090/3991

Abstract: A nodule localization system includes a localization structure. The localization structure is arranged to extend from a nodule to a suture, and the entire coil can be located in the lung such that the suture extends through the pleural space. During normal respiration or other movement, the suture will move to be positioned mostly or entirely in the pleural space such that a surgeon can follow the suture to the coil and resect the nodule.

公开(公告)号：US08936795B2

公开(公告)日：2015-01-20

申请号：US13720135

申请日：2012-12-19

Applicant: Regents of the University of Minnesota

Inventor： Jafar Golzarian ,  Lihui Weng

IPC: A61M5/178 ,  A61M25/00 ,  A61L24/04 ,  A61M5/19 ,  A61L31/04 ,  A61L31/14 ,  A61L31/16 ,  A61L31/18

CPC classification number: A61L24/043 ,  A61L31/041 ,  A61L31/145 ,  A61L31/16 ,  A61L31/18 ,  A61L2430/36 ,  A61M5/178 ,  A61M5/19 ,  C08L5/08 ,  C08L1/28

Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.

Abstract translation: 液体栓塞材料可以包括在第一溶剂中包含约1.2％至约2.5％重量/体积（w / v）羧甲基壳聚糖（CCN）的第一溶液和包含约1.2％至约2.5％的第二溶液的混合物 ％w / v氧化的羧甲基纤维素（OCMC）在第二溶剂中。 液体栓塞材料可以用于通过混合第一溶液和第二溶液来栓塞目标栓塞位置以形成液体栓塞材料（或水凝胶前体材料），将水凝胶前体材料引入到体内的目标栓塞位置 患者，并允许CCN和OCMC反应形成水凝胶材料并栓塞目标栓塞位置。